Trial Profile
A 7-month, Multicenter Study to Evaluate the Efficacy of Intravitreal Injections of Aflibercept (EYLEA) 2mg /0.05 ml as Secondary or Third Line Treatment for Neovascular Age-related Macular Degeneration (NVAMD).
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 09 May 2019
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- 12 Jan 2016 Planned End Date changed from 1 Dec 2015 to 1 Apr 2016 as reported by ClinicalTrials.gov.
- 12 Jan 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Apr 2016 as reported by ClinicalTrials.gov.
- 21 Sep 2015 Planned End Date changed from 1 Sep 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov.